Download Atlanpole Biotherapie

Competitiveness Cluster:
Atlanpole Biotherapies
Thematics: Biotechnologies / Health
Main interests
Immunology and immunotherapy
Radiopharmaceuticals (“Isotop4Life”)
Regenerative Medicine
Keys Figures
Financed projects : 59
Total cost of the projects: 184.3 M€
1
- FUI projects: 24.8 M€
2
- NRA projects: 42.3 M€
Achieved projects : 46
Patents (2011) : 48
Scientifics articles (2011) : 29
171 Members
4 intermediate-sized and large enterprises:
Groupe Grimaud, Eurofins, Silliker SAS,… including
2 foreign companies: The MarkeTech Group (USA),
Thermo Fisher Scientific (USA)
69 SMEs
98 centers of excellence: Universities of Angers and
Nantes, Cancer Center ICO, ITUN (Transplantation
Institute)…
Figures : End 2011
(from evaluation 2012, 2008-2011 period )
Cluster Strengths
Number of employees at cluster members: 1 900
Atlanpole Biotherapies is characterized by a fast increase of researchers number over the past decade
– almost 1000 specialists dedicated to life-science - and the average development of 3 new biotech
start ups every year. In order to ensure skilled people for the development of advanced therapies, a
new training center, BIOPRACTIS, enables continuing education in clean rooms and training on the
biopharmaceuticals producing process with pilot-scale industrial equipments.
Atlanpole Biotherapies members focus their efforts on 3 major therapeutic areas:
•
1
2
Immunobiotherapies with two specific focuses in tumor vaccination and autoimmune
diseases/transplantation.
We benefit from a strong history in the field of immunology with first applications designed for the
transplantation and oncology therapeutic armamentarium development. This excellence lead to
many company creations directly involved in, or related to, the business of antibodies or tumor
vaccines. More recently the performance of the immunology community was rewarded by the French
government granting the “IGO Labex” (“Immuno Graft Oncology laboratory of excellence) and of the
“IHU CESTI project” (European Clinical Center for Transplantation Sciences). These two projects
aim not only at improving recent developments in diagnostics and therapies in transplantation or
oncology but also at developing next generation tools. Thus alternatives to organ grafts are
developed and tested with cell and gene therapies techniques as well as combined biologics
FUI : Single Interministerial Fund provides support for R&D projects between firms and laboratories from French cluster
NRA : French National Research Agency provides support for academics projects
approaches. Among audacious strategies developed in these projects, we can also mention the use
of innovative radioisotopes that can be produced in the Arronax High-Energy cyclotron.
•
Radiopharmaceuticals with the creation of a dedicated hub “ISOTOP-4-LIFE”mixing academic &
private competencies.
Intensive research in nuclear imaging, targeted radionuclide therapy with radio-immunotherapy (RIT)
and radiobiology is being performed around the high-energy and high-intensity cyclotron Arronax in
Nantes. The main developments underway in nuclear imaging consist in innovative technologies for
oncology, neurology and cardiac applications as well as improved measurement of
radiopharmaceuticals biodistribution. RIT has shown promising results in clinical trials against
cancers resistant to other treatments. RIT for cancers with poor prognosis is a focus of our cluster
with special emphasis on a proprietary radio-labeled monoclonal antibody with completed Phase II
clinical development to fight residual prostate cancer. Finally Atlanpole Biotherapies provides a
comprehensive value chain for assessing your lead compounds namely trough a fully operating and
open access “Whole Body Imaging HUB”.
•
Regenerative medicine including biomaterials as well as advanced therapies using cells and genes.
Our strategy is supported by strong medical expertises in oncology, dermatology, cardiology,
orthopedia and rare diseases and by specialized core facilities for immunomonitoring,
biomanufacturing, developing and supplying a wide range of synthetic or viral carriers and by a
strong know-how in experimental preclinical surgery and in safety tests development. Our community
is also committed in various ambitious projects:
• C4C, a national project aiming at structuring the large scale manufacturing of cell based therapeutic
products. Our members are also leading a gene therapy manufacturing initiative (PGT industrial
demonstrator facility).
• The European R&D projects GAMBA (Gene Activated Matrices for Bone and Cartilage
Regeneration in Arthritis) and REBORNE (Regenerating Bone Defects using New biomedical
Engineering approaches) illustrate the strengths in the field of orthopedia. These successes also rely
on a strong European networking culture of our players.
An example of R&D Projects
- GelTOP:
The GelTOP collaborative project aims to
develop hydrogels for in situ release of active
ingredients in difficult situations such as bone
tumors or unconsolidated fractures and thus
allow bone reconstruction. Between 2009 to
2013, Biomatlante, the company project leader,
developed an anticancer active ingredients
encapsulation and controlled release system,
to be more accurate and less invasive in
complicated situations. The benefit for the
patient is to prevent overdoses and successive
medication. The company appealed to Inserm UMR 957 - to develop anticancer peptides, and
to Atlantic Bone Screen company to undertake
in vitro and in vivo trials..
Existing collaborations
BCRT, BIOTOP, BIOREGIO Stern, Biome Tie.V,
Heidelberg Technology Park, Germany
Baltic Innovation Agency, Estonia
Cardiff
University,
MEDILINK,
Cornwall
Development Company, UK
SAN RAFFAELE Institut, Italy
West BIC Galway, Ireland
Insituto Andaluz de tecnologia, BIOMADRID,
Spain
ADRAL, UERN, Portugal
BIOWIN, Belgium
UPPSALA BIO, Sweden
GOTEBORG BIO, Norway
MEDCOAST Scandinavia, many countries
LIOF, Netherland
BIOPEOPLE, Denmark
Contact
e-mail for International Affairs: [email protected]
web site : http://www.atlanpolebiotherapies.eu/
www.competitivite.gouv.fr
www.competitivite.gouv.fr/en
www.competitivite.gouv.fr/es
Update : 01/09/2013